I-Gen Biomics Private Limited - Due diligence report

A 360° intelligence report on I-Gen Biomics Private Limited: trust score, financial health, credit view, compliance, directors, growth and d…

2016-04-26 New Delhi, Delhi Active Unlisted Active Compliant
Share
View plans
IB I-Gen Biomics Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

I-Gen Biomics Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
85/100
Trust Score
Low Risk

I-Gen Biomics Private Limited is assessed as Low Risk with a Trust Score of 85/100. I-Gen Biomics Private Limited is an active private limited indian non-government company incorporated in 2016, operating in the Healthcare sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 02 Jul 2026 from the latest processed filings. I-Gen Biomics Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
85/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
ABHISHEK KANJLIA 01234567 Director 01/04/2018 6 yrs Approved
SHAILY GUPTA 01234567 Director 01/04/2018 6 yrs Approved
SAPNA NARULA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 55 · Distress 75
Growth signals & trust indicators
Net margin improved to 2.1x.
Operating for 10+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment66/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view64/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 8 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
06 Sep 2021
Director ceased
RAKESH DIMRI
30 Dec 2020
Director ceased
SAPNA NARULA
01 Jul 2020
Director appointed
SAPNA NARULA (Director)
26 Apr 2016
Incorporated
Registered with Roc Delhi I
Director appointed
ABHISHEK KANJLIA (Director)
Director appointed
SHAILY GUPTA (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Avinash Techno Solutions Private Limited U52100GJ2008PTC053399 Vadodara, Gujarat, India
Fegade Patil Farmers Producer Company Limited U01400MH2019PTC322851 Hingoli, Maharashtra, India
Eryx Engineering Pvt Ltd U45203AS1991PTC003617 Guwahati, Assam, India
Endosys Technologies Private Limited U52190TN2016PTC111115 Chennai, Tamil Nadu, India
Mpk Enterprises Private Limited U17291PN2013PTC146752 Pune City, Maharashtra, India
Al Rafay Agro Foods Private Limited U15132DL2013PTC249204 New Delhi, Delhi, India
Shreesakti Traders Private Limited U51909WB2012PTC173571 Kolkata, West Bengal, India
Aathika Lifestyle Private Limited U32100TZ2019PTC032948 Salem, Tamil Nadu, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify I-Gen Biomics Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of I-Gen Biomics Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for I-Gen Biomics Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether I-Gen Biomics Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for I-Gen Biomics Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is I-Gen Biomics Private Limited an active company?

I-Gen Biomics Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is I-Gen Biomics Private Limited financially healthy?

I-Gen Biomics Private Limited has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with I-Gen Biomics Private Limited?

Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls I-Gen Biomics Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does I-Gen Biomics Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is I-Gen Biomics Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to I-Gen Biomics Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.